U.S. markets closed
  • S&P Futures

    4,166.75
    -9.50 (-0.23%)
     
  • Dow Futures

    34,018.00
    -63.00 (-0.18%)
     
  • Nasdaq Futures

    13,994.75
    -34.75 (-0.25%)
     
  • Russell 2000 Futures

    2,255.10
    -3.90 (-0.17%)
     
  • Crude Oil

    62.85
    -0.28 (-0.44%)
     
  • Gold

    1,776.70
    -3.50 (-0.20%)
     
  • Silver

    26.00
    -0.11 (-0.42%)
     
  • EUR/USD

    1.1975
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3832
    +0.0048 (+0.35%)
     
  • USD/JPY

    108.7530
    +0.0370 (+0.03%)
     
  • BTC-USD

    56,669.60
    -4,699.88 (-7.66%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.67 (+0.14%)
     

Amgen's multiple myeloma drug falls short in late stage study

Sept 27 (Reuters) - Amgen Inc said on Tuesday its cancer drug Kyprolis failed to meet the main goal of a late-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diagnosed multiple myeloma.

The Phase III study evaluated Kyprolis in combination with chemotherapy drug, melphalan and immunosuppressant prednisone.

The U.S. Food and Drug Administration approved Kyprolis in January when administered in combination with certain other therapies to treat patients with multiple myeloma.

(Reporting by Abinaya Vijayaraghavan in Bengaluru; Editing by Sunil Nair)